Biopharmaceutical Manufacturing Market: Growth, Size, Share, and Trends

Biotechnology Contract Manufacturing Market | Biopharmaceutical Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2028

Report Code: BT 8780 Sep, 2023, by marketsandmarkets.com

Market Growth Outlook Summary

The global biotechnology contract manufacturing market growth forecasted to transform from USD 16.6 billion in 2023 to USD 24.8 billion by 2028, driven by a CAGR of 8.3%. The growth of biopharmaceutical manufacturing market is majorly driven by factors like increasing approvals of monoclonal antibodies and, in other targeted therapies, rising approvals of biosimilars. Increasing investments for the expansion of production capacities among the contract manufacturers will support the growth of the market in the future. Moreover, factors like increasing investments for research in novel therapeutics like cell and gene therapy and antibody drug conjugates are likely to support the market growth.

Biologics Contract Manufacturing Market - Global Forecast to 2028

Biologics Contract Manufacturing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Biopharmaceutical Manufacturing Market

Biotechnology Contract Manufacturing Market Dynamics

DRIVER: Increasing biologics manufacturing outsourcing trend among biopharmaceutical companies

The increasing popularity of biologics in medicine has led to a significant rise in outsourcing manufacturing. Biologics contract manufacturers have the know-how and setup to make these complex therapies effective while ensuring the meeting of strict quality rules and regulations. Such contract manufacturers have a deep understanding of protein chemistry, cell culture, downstream process, and the impact of process conditions on yield and protein structure while proceeding from lab to GMP scale. Therefore, biopharmaceutical companies prefer to opt for a highly efficient way to accelerate development and manufacturing by partnering with CDMOs, and CMOs have strong expertise in biologics, chemistry manufacturing control, and commercial manufacturing. Further, biopharmaceutical companies outsource clinical and commercial biomanufacturing to reduce the cost and associated risk with in-house development and manufacturing. This, in turn, supports the biopharmaceutical contract manufacturing market growth.

RESTRAINT: Intellectual property rights issues

Intellectual property protection is the most vital part of contract manufacturing. An innovator company has to share the complete details of its patented drug with the contract manufacturer to allow it to manufacture the drug. It includes the risk of using the information in an unauthorized manner and duplicating the products and the risk associated with infringements. Recently, the outsourcing of basic manufacturing activities is emerged as an upcoming trend in the industry. For example, pharmaceutical firms are outsourcing the manufacturing of complex biologics as it requires the expertise and infrastructure to manufacture them in a manner that meets individual patient requirements. For this trend to continue in the biopharmaceutical contract manufacturing market, it is necessary to maintain an honest relationship between the pharmaceutical companies and the CMOs to ensure the protection of intellectual property.

OPPORTUNITY: Rising demand for cell therapies and gene therapies

Cell and gene therapies are highly specific and have the potential to address unmet medical needs associated with treating untouched disorders by small molecule drugs and other biologics. Their promising therapeutic potential has led many pharmaceutical companies to focus on developing and commercializing these therapies. This has led to increased demand for cell and gene therapy development and manufacturing. As of April 2022, more than 20 cell & gene therapies have been approved by the US FDA. The growing number of cell and gene therapy candidates, along with their progression through the various phases of clinical development and their complex manufacturing process, has increased the demand for facilities that offer manufacturing services for these therapies. This is likely to provide growth opportunities for the contract manufacturing of these therapies.

CHALLENGE: Challenges to meet reformed regulations

FDA regulations outline that the manufacturer needs to strictly follow the guidelines defined by the respective regulatory authority. The CMOs face the task of seeking regulatory approvals from different regions for the same molecule, tailoring their submissions based on specific client requirements. This process becomes complex due to variations in regulations and submission criteria across different countries. Mistakes in this complex attempt can pose significant obstacles for innovators aiming to access regulated markets. This challenge is deepened by the need to align manufacturing practices with the latest regulatory reforms. Thus making it challenging for CMOs to consistently meet evolving standards across diverse regions and countries.

Biopharmaceutical Manufacturing Market Ecosystem

The global biopharmaceutical contract manufacturing market is a complex ecosystem involving various stakeholders, including the supply side, i.e., companies providing contract manufacturing services, and the demand side, i.e., pharmaceutical companies and biotechnology companies, among others.

Several key companies provide services for contract manufacturing. For example, Lonza (Switzerland) is a leading provider of contract manufacturing services for biologics, including cell and gene therapies, viral vectors, and plasmid DNA. Other service providers include Thermo Fisher Scientific, Inc. (US), AbbVie, Inc. (US), Catalent Inc. (US), Wuxi Biologics (China), and others.

Biotechnology Contract Manufacturing Market Ecosystem

The manufacturing segment dominated the biotechnology contract manufacturing industry by service.

The manufacturing segment held the largest share of the global biotechnology contract manufacturing market in 2022. The manufacturing of biopharmaceuticals includes processes like upstream manufacturing and downstream manufacturing. As the manufacturing of biologics involves complex processes, the process design, optimization, and deployment of enhanced protocols and procedures to obtain purity is still an ongoing challenge for biopharmaceutical companies. Biologic manufacturers can fulfill their production goals while staying ahead of ever-changing trends and technologies, supporting the trend for outsourced manufacturing.

The biologic drug substance manufacturing segment dominated the biotechnology contract manufacturing industry by type.

The biologic drug substance manufacturing segment held the largest share of the global biopharmaceutical contract manufacturing market in 2022. The large share of drug substance manufacturing is attributed to the growing research in the field of novel therapies to treat chronic diseases.  As the marketed drugs are moving toward the patent cliff, there is an increasing demand for newer targeted therapies like monoclonal antibodies, cell therapies, and gene therapies. Whereas the manufacturing of these complex drug substances requires highly sophisticated equipment and manufacturing technologies. The innovator companies prefer to outsource the manufacturing of these biological drug substances, in turn supporting the market growth.

Asia Pacific region of the biotechnology contract manufacturing industry is estimated to register the highest CAGR during the forecast period.

Asia Pacific offers lucrative growth potential for the biotechnology contract manufacturing market. This can be attributed to the increasing pharmaceutical R&D spending in the region, the growing trend of outsourcing manufacturing services, and increasing government initiatives for healthcare research. One significant growth driver for the market in the Asia Pacific region is the increasing investment in healthcare infrastructure and R&D activities. Further, the growing prevalence of chronic diseases and the large population in the region are also facilitating the demand for novel therapies for treatment, supporting the demand for biologic drugs and their outsourced manufacturing. Also, the favorable regulatory guidelines for drug approval in the region are expected to drive biopharmaceutical contract manufacturing market growth.

Biotechnology Contract Manufacturing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the biologics contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holding Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC, Inc. (Japan), Merck KgaA (Germany), JSR Corporation (Japan), among others.

Scope of the Biopharmaceutical Manufacturing Market

Report Metric

Details

Market Revenue Size in 2023

$16.6 billion

Projected Revenue Size by 2028

$24.8 billion

Industry Growth Rate

Poised to grow at a CAGR of 8.3%

Market Driver

Increasing biologics manufacturing outsourcing trend among biopharmaceutical companies

Market Opportunity

Rising demand for cell therapies and gene therapies

This report categorizes the Biotechnology contract manufacturing market to forecast revenue and analyze trends in each of the following submarkets:

By Service

  • Manufacturing
  • Formulation and Fill-Finish
  • Packaging and Labeling
  • Other services

By Type

  • Biologic Drug Substance Manufacturing
  • Biologic Drug Product Manufacturing

By Scale of Operation

  • Commercial Operations
  • Clinical Operations

By Source

  • Mammalian Expression Systems
  • Non-Mammalian Expression Systems

By Molecule

  • Monoclonal Antibodies
  • Cell Therapy & Gene Therapy
  • Antibody-Drug Conjugates (ADCs)
  • Vaccines
  • Therapeutic Peptides & Proteins
  • Other Molecule Types

By Therapeutic Area

  • Oncology
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Neurology
  • Other Therapeutic Areas

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
    • Brazil
    • Rest of Latin America
  • Middle East and Africa (MEA)

Recent Developments of Biologics Contract Manufacturing Market

  • In January 2023, WuXi Biologics entered into a licensing agreement with GSK plc for using WuXi Biologics’ proprietary technology platforms. Under this, GSK was granted an exclusive global license for the research, development, manufacturing, and commercialization of bispecific antibodies in the WuXi Biologics plan.
  • In October 2022, Samsung Biologics partnered with GSK plc for the manufacturing of GSK’s monoclonal antibody and products, including lupus treatments like Benlysta.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

INTRODUCTION
26
RESEARCH METHODOLOGY
31
EXECUTIVE SUMMARY
44
PREMIUM INSIGHTS
48
MARKET OVERVIEW
52
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising demand for biologics and biosimilars
    - Increasing outsourcing of biologics manufacturing among biopharmaceutical companies
    - Growing focus on personalized medicine
    - Increasing collaborations between pharmaceutical companies and biologics CMOs
    - Advancements in manufacturing technologies
    RESTRAINTS
    - Intellectual property rights issues
    OPPORTUNITIES
    - Rising demand for cell and gene therapies
    - Significant growth opportunities offered by emerging countries
    - Expansion of biologics manufacturing capacities by CMOs
    - Strong emphasis on drug development
    CHALLENGES
    - Complying with regulatory reforms
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 TECHNOLOGY ANALYSIS
  • 5.7 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 KEY CONFERENCES AND EVENTS IN 2023–2024
  • 5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE
75
  • 6.1 INTRODUCTION
  • 6.2 MANUFACTURING
    SHIFT TOWARD SINGLE-USE TECHNOLOGY TO DRIVE MARKET
  • 6.3 FORMULATION & FILL-FINISH
    MOST CRITICAL ASPECT OF BIOLOGICS MANUFACTURING
  • 6.4 PACKAGING & LABELING
    FINAL CHECKPOINT BEFORE PRODUCT REACHES PATIENT
  • 6.5 OTHER SERVICES
BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE
88
  • 7.1 INTRODUCTION
  • 7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING
    INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET
  • 7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING
    INCREASING R&D COST AND PROCESS COMPLEXITY PROMPTED SHIFT TOWARD CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS
BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
96
  • 8.1 INTRODUCTION
  • 8.2 COMMERCIAL OPERATIONS
    INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH
  • 8.3 CLINICAL OPERATIONS
    INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET
BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE
104
  • 9.1 INTRODUCTION
  • 9.2 MAMMALIAN EXPRESSION SYSTEMS
    VERSATILE THERAPEUTIC DIVERSITY TO DRIVE MARKET
  • 9.3 NON-MAMMALIAN EXPRESSION SYSTEMS
    INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH
BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE
113
  • 10.1 INTRODUCTION
  • 10.2 MONOCLONAL ANTIBODIES
    GROWING APPROVALS FOR MABS TO PROPEL MARKET
  • 10.3 CELL & GENE THERAPIES
    INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • 10.4 ANTIBODY-DRUG CONJUGATES
    INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH
  • 10.5 VACCINES
    INCREASING DEMAND FOR VACCINES TO DRIVE MARKET
  • 10.6 THERAPEUTIC PEPTIDES & PROTEINS
    INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH
  • 10.7 OTHER MOLECULE TYPES
BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA
135
  • 11.1 INTRODUCTION
  • 11.2 ONCOLOGY
    INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET
  • 11.3 AUTOIMMUNE DISEASES
    RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET
  • 11.4 METABOLIC DISEASES
    INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS
  • 11.5 CARDIOVASCULAR DISEASES
    DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
  • 11.6 NEUROLOGY
    HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
  • 11.7 INFECTIOUS DISEASES
    RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH
  • 11.8 OTHER THERAPEUTIC AREAS
BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY REGION
159
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    US
    - Presence of large number of FDA-approved manufacturing facilities to favor market growth
    CANADA
    - Rising government funding for drug development to support market growth
    RECESSION IMPACT
  • 12.3 EUROPE
    GERMANY
    - Rapidly growing pharmaceutical market to drive market
    UK
    - Rising investments in drug development to favor market growth
    FRANCE
    - Availability of funds from government and private organizations for domestic drug development to support market growth
    ITALY
    - Rising commercial drug development pipeline to drive market
    SPAIN
    - Rising R&D expenditure to propel market
    REST OF EUROPE
    RECESSION IMPACT
  • 12.4 ASIA PACIFIC
    CHINA
    - Low manufacturing cost and high demand for medicines to favor market growth
    JAPAN
    - Growing demand for biosimilars to drive growth
    SOUTH KOREA
    - Increasing R&D activities for drug development to drive market
    INDIA
    - Increasing pharma R&D activities and government funding for biotechnology industry to support market growth
    REST OF ASIA PACIFIC
    RECESSION IMPACT
  • 12.5 LATIN AMERICA
    BRAZIL
    - Growing pharmaceutical industry to drive market
    REST OF LATIN AMERICA
    RECESSION IMPACT
  • 12.6 MIDDLE EAST & AFRICA
    GROWING PHARMACEUTICALS INDUSTRY TO SUPPORT MARKET GROWTH
    RECESSION IMPACT
COMPETITIVE LANDSCAPE
237
  • 13.1 INTRODUCTION
  • 13.2 REVENUE SHARE ANALYSIS
  • 13.3 MARKET SHARE ANALYSIS
  • 13.4 COMPANY EVALUATION MATRIX
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
  • 13.5 COMPETITIVE BENCHMARKING
    COMPANY FOOTPRINT ANALYSIS
    COMPANY FOOTPRINT ANALYSIS, BY MOLECULE TYPE
    COMPANY FOOTPRINT ANALYSIS, BY REGION
  • 13.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
    PROGRESSIVE COMPANIES
    STARTING BLOCKS
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
  • 13.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
  • 13.8 COMPETITIVE SCENARIO AND TRENDS
    DEALS
    OTHER DEVELOPMENTS
COMPANY PROFILES
253
  • 14.1 KEY PLAYERS
    LONZA
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    WUXI BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    CATALENT, INC.
    - Business overview
    - Services offered
    - Recent developments
    SAMSUNG BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    - Business overview
    - Services offered
    - Recent developments
    FUJIFILM HOLDINGS CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    ABBVIE INC.
    - Business overview
    - Services offered
    - Recent developments
    EUROFINS SCIENTIFIC
    - Business overview
    - Services offered
    - Recent developments
    GENSCRIPT BIOTECH CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    AGC INC.
    - Business overview
    - Services offered
    - Recent developments
    MERCK KGAA
    - Business overview
    - Services offered
    - Recent developments
    JSR CORPORATION
    - Business overview
    - Services offered
    - Recent developments
  • 14.2 OTHER PLAYERS
    STELIS
    RECIPHARM AB
    EMERGENT
    SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.
    LOTTE BIOLOGICS
    HEPALINK GROUP
    CURIA GLOBAL, INC.
    JRS PHARMA
    MINAPHARM PHARMACEUTICALS
    RENTSCHLER BIOPHARMA SE
    AVID BIOSERVICES, INC.
    ABZENA LTD.
    POLYPLUS TRANSFECTION
    MIDAS PHARMA GMBH
    MABPLEX INTERNATIONAL CO., LTD.
    ASAHI KASEI CORPORATION
APPENDIX
315
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
  • TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
  • TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
  • TABLE 4 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS
  • TABLE 5 LIST OF EXPANSIONS BY TOP COMPANIES
  • TABLE 6 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY
  • TABLE 7 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: ROLE IN ECOSYSTEM
  • TABLE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 REGULATORY SCENARIOS ACROSS DIFFERENT COUNTRIES/REGIONS
  • TABLE 14 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • TABLE 15 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 16 BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 17 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 18 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 19 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 20 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 21 BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 22 NORTH AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 23 EUROPE: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 24 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 25 LATIN AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 26 BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 27 NORTH AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 28 EUROPE: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 30 LATIN AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 31 OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 32 NORTH AMERICA: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 33 EUROPE: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 35 LATIN AMERICA: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 36 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 37 BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 38 NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 39 EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 41 LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 42 BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 43 NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 44 EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 46 LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 47 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 48 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 49 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 50 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 52 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 53 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 55 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 57 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 58 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 59 TYPES OF MAMMALIAN EXPRESSION SYSTEMS
  • TABLE 60 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 61 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 62 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 64 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 65 TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS
  • TABLE 66 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 67 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 68 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 70 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 71 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 72 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 73 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 74 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 76 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 77 FDA-APPROVED CAR T-CELL THERAPIES
  • TABLE 78 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 79 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 80 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 82 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 83 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 84 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 85 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 87 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 88 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)
  • TABLE 89 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 90 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 91 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 93 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 94 EXAMPLES OF PEPTIDE THERAPEUTICS
  • TABLE 95 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE
  • TABLE 96 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 97 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 98 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 100 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 101 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 102 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 103 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 105 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 106 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 107 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 108 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 109 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 111 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 112 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 113 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 114 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 116 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 117 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 118 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 119 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 121 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 122 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 123 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 124 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 126 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 127 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 128 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 129 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 131 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 132 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 133 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 134 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 136 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 137 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 138 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 139 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 141 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 142 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 143 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 144 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 145 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 146 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 147 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 148 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 149 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 150 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 151 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 152 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 153 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 154 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 155 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 156 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 157 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 158 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 159 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 160 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 161 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 162 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 163 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 164 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 165 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 166 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 167 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 168 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 169 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 170 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 171 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 172 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 173 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 174 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 175 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 176 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 177 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 178 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 179 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 180 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 181 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 182 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 183 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 184 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 185 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 186 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 187 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 188 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 189 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 190 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 191 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 192 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 193 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 194 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 195 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 196 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 197 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 198 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 199 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 200 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 201 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 202 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 203 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 204 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 212 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 213 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 214 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 215 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 216 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 217 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 218 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 219 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 220 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 221 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 222 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 223 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 224 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 225 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 226 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 227 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 228 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 229 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 230 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 231 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 232 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 233 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 234 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 235 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 237 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 238 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 242 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 243 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 244 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 245 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 246 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 247 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 248 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 249 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 250 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 251 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 252 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 253 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 254 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 255 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 256 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 257 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 258 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 259 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 260 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 261 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)
  • TABLE 262 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 263 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
  • TABLE 264 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)
  • TABLE 265 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)
  • TABLE 266 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
  • TABLE 267 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
  • TABLE 268 COMPANY FOOTPRINT ANALYSIS
  • TABLE 269 MOLECULE TYPE FOOTPRINT ANALYSIS OF COMPANIES
  • TABLE 270 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES
  • TABLE 271 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 272 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS
  • TABLE 273 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2020–JULY 2023
  • TABLE 274 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JULY 2023
  • TABLE 275 LONZA: BUSINESS OVERVIEW
  • TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
  • TABLE 277 WUXI BIOLOGICS: BUSINESS OVERVIEW
  • TABLE 278 CATALENT, INC.: BUSINESS OVERVIEW
  • TABLE 279 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
  • TABLE 280 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
  • TABLE 281 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
  • TABLE 282 ABBVIE INC.: BUSINESS OVERVIEW
  • TABLE 283 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
  • TABLE 284 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
  • TABLE 285 AGC INC.: BUSINESS OVERVIEW
  • TABLE 286 MERCK KGAA: BUSINESS OVERVIEW
  • TABLE 287 JSR CORPORATION: BUSINESS OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 3 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
  • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2022
  • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS, 2022
  • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
  • FIGURE 9 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 12 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 13 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET
  • FIGURE 15 RISING APPROVALS OF BIOLOGICS TO DRIVE MARKET
  • FIGURE 16 COMMERCIAL OPERATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • FIGURE 17 ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028
  • FIGURE 18 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028
  • FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 20 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 NUMBER OF APPROVED BIOLOGICS, 2015–2022
  • FIGURE 22 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015–2022
  • FIGURE 23 PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015–2022
  • FIGURE 24 VALUE CHAIN ANALYSIS OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: MANUFACTURING AND DISTRIBUTION PHASES ADD MAXIMUM VALUE
  • FIGURE 25 ECOSYSTEM ANALYSIS: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET
  • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOTECHNOLOGY CMO SERVICES
  • FIGURE 27 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 28 NUMBER OF APPROVED MONOCLONAL ANTIBODIES, 2010–2022
  • FIGURE 29 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 30 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 31 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
  • FIGURE 33 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
  • FIGURE 34 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
  • FIGURE 35 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
  • FIGURE 36 LONZA: COMPANY SNAPSHOT (2022)
  • FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 38 WUXI BIOLOGICS: COMPANY SNAPSHOT (2022)
  • FIGURE 39 CATALENT, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 40 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
  • FIGURE 41 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
  • FIGURE 42 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 43 ABBVIE INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 44 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
  • FIGURE 45 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 46 AGC INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022)
  • FIGURE 48 JSR CORPORATION: COMPANY SNAPSHOT (2022)

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the biotechnology contract manufacturing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Bioprocess and Biosystems Engineering, Bioprocess International, PLOS Biology, European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Parenteral Drug Association (PDA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), and World Journal of Pharmaceutical Sciences. Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the biotechnology contract manufacturing market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the biotechnology contract manufacturing market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical and biopharmaceutical industries, academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, and marketing & sales managers of key service providers. These interviews were conducted across four major regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Biotechnology Contract Manufacturing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the biotechnology contract manufacturing market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the contract manufacturing business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Market Size Estimation Methodology-bottom-up approach

Biotechnology Contract Manufacturing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Market Size Estimation Methodology-top-down approach

Biotechnology Contract Manufacturing Market Size, and Share

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Biotechnology contract manufacturing involves outsourcing biological manufacturing services to specialized contract manufacturing organizations (CMOs). Biologics are complex pharmaceutical products derived from living organisms, such as proteins, peptides, nucleic acids, cells or tissues, and other biotechnologically produced molecules. The market study includes the assessment of various services, sources, types, scale of operation, molecules, and therapeutic areas in biotechnology contract manufacturing.

Key Stakeholders

  • Pharmaceutical and Biotechnology Companies
  • Research and Consulting Firms
  • Academic Medical Centers
  • Government Research Organizations
  • Clinical Research Institutes
  • Contract Research Organizations
  • Pharmaceutical Distributors and Suppliers
  • Corporate Entities
  • Contract Development and Manufacturing Organizations

Report Objectives

  • To define, describe, and forecast the biotechnology contract manufacturing market based on service, type, source, scale of operation, molecule  type, therapeutic area, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the Rest of Europe biotechnology contract manufacturing market, by country
  • Further breakdown of the Rest of Asia Pacific biotechnology contract manufacturing market, by country
  • Further breakdown of the Latin America and Middle East & Africa biotechnology contract manufacturing market, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Further breakdown of the Therapeutic Areas segment
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
BT 8780
Published ON
Sep, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Biotechnology Contract Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
knowledgestore logo

Hold On!

Want to explore hidden markets that can drive new revenue in Biotechnology Contract Manufacturing Market?

Find Hidden Markets
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback